Cancer News and Research

Latest Cancer News and Research

Oral bisphosphonates outweigh the risk associated with jaw disease

A commonly prescribed osteoporosis drug is associated with a slightly elevated risk of developing the rare, but serious condition, osteonecrosis of the jaw; nonetheless the risk remains extremely low. These findings are published online in the Journal of Dental Research, the official journal of the International and American Associations for Dental Research.

14 Feb 2011

Heavy alcohol intake can lead to increased risk of AF

Atrial Fibrillation is the most common cardiac arrhythmia. Its name comes from the fibrillating of the heart muscles of the atria, instead of a coordinated contraction. The result is an irregular heartbeat, which may occur in episodes lasting from minutes to weeks, or it could occur all the time for years. Atrial fibrillation alone is not in itself generally life-threatening, but it may result in palpitations, fainting, chest pain, or congestive heart failure.

14 Feb 2011

Fiber in diet protects from more than just heart disease and diabetes: Study

In one of the largest studies of its kind, researchers have identified a link between high-fiber diets and lower risks of death not only from heart disease, but from infectious and respiratory illnesses as well. This government commissioned study also ties fiber with a lower risk of cancer deaths in men, but not women, possibly because men are more likely to die from cancers related to diet, like cancers of the esophagus. And it finds the overall benefit to be strongest for diets high in fiber from grains.

14 Feb 2011

bioMD makes offer for Allied Medical

bioMD Limited (ASX: BOD), a company with assets in regenerative tissue engineering technologies today announced that it has made an offer to buy all of the shares in Allied Medical Limited (Allied), a public unlisted company that specialises in the sales, distribution and commercialisation of medical technologies.

14 Feb 2011

U-Systems completes pivotal study for automated breast ultrasound cancer screening

U-Systems, the leader in automated breast ultrasound today announced the completion of a pivotal ROC Reader Study for automated breast ultrasound cancer screening. Conducted by University of Chicago, an acclaimed pioneer in women's heath research, the multi-reader, multi-case (MRMC) ROC Reader Study was carried-out to evaluate the sensitivity of somo•v™ Automated Breast Ultrasound (ABUS) together with a screening mammogram in detecting breast cancer in women with dense breast tissue.

14 Feb 2011

Cord Blood America purchases minority interest in Stem Cells VIDAPLUS

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has purchased a minority interest in Stem Cells VIDAPLUS, a Spanish-owned company which preserves umbilical cord stem cells at the Institute of Transfusion Medicine and Immunology of the Red Cross in Frankfurt, Germany.

14 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

NHGRI's new strategic plan to identify genetic bases of most single-gene disorders

A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).

14 Feb 2011

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

AngioDynamics announced today the launch of a new Morpheus® SMART PICC bedside insertion kit and new 5 French Dual Lumen Peripherally Inserted Central Catheter (PICC) as part of the continued growth of its Morpheus SMART PICC line.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Vitamin D levels not linked to prostate cancer development

Vitamin D levels do not affect men's chances of developing prostate cancer, according to new research published in the journal Cancer Causes and Control.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

Sequencing of whole prostate cancer genomes - an historic development

Today's announcement regarding the sequencing of whole prostate cancer genomes is an historic development in the fight against prostate cancer. The ability to sequence whole genomes will spare some patients from unnecessary treatments and side effects while eliminating an estimated $1.5 billion that is spent each year on overtreatment. The complete research findings will be published in the February 10 issue of Nature.

14 Feb 2011

SynthRx to become wholly-owned subsidiary of ADVENTRX

ADVENTRX Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement to acquire SynthRx, Inc., a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188.

14 Feb 2011

Oestrogen reduces risk of breast cancer: Study

A team of researchers at CIC bioGUNE has revealed that oestrogen can reduce the risk of breast cancer. Their work shows that oestrogen is capable of reducing the number of breast cancer stem cells, which may explain the lower aggression of the tumour and, as a consequence, the possibility of a better prognosis.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

UH Case Stroke and Cerebrovascular Center increases tPA use for ischemic stroke by 13.5 times

University Hospitals Stroke and Cerebrovascular Center recently reported that it has increased the use of tPA or "clot busting therapy" for ischemic stroke by 13.5 times throughout UH system hospitals since implementing the System Stroke Program. Launched in 2008, SSP sought to increase access to the lifesaving treatment for acute ischemic stroke patients in the 15 counties surrounding Cleveland.

14 Feb 2011

Cancer News and Research

Latest Cancer News and Research

Oral bisphosphonates outweigh the risk associated with jaw disease

Heavy alcohol intake can lead to increased risk of AF

Fiber in diet protects from more than just heart disease and diabetes: Study

bioMD makes offer for Allied Medical

U-Systems completes pivotal study for automated breast ultrasound cancer screening

Cord Blood America purchases minority interest in Stem Cells VIDAPLUS

BioTime to merge Glycosan with OrthoCyte

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

NHGRI's new strategic plan to identify genetic bases of most single-gene disorders

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Vitamin D levels not linked to prostate cancer development

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Sequencing of whole prostate cancer genomes - an historic development

SynthRx to become wholly-owned subsidiary of ADVENTRX

Oestrogen reduces risk of breast cancer: Study

JDR releases research report on Osteonecrosis of the jaw

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

UH Case Stroke and Cerebrovascular Center increases tPA use for ischemic stroke by 13.5 times

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in